Classes of novel drugs: Since i have both p5... - CLL Support

CLL Support

22,474 members38,612 posts

Classes of novel drugs

10 Replies

Since i have both p53 and p17 . Novel drugs are all i will have since chemo not effective and i really don't want a transplant.

gazyva and its successors

venetolax and its successors.

ibrutinib and its successors

I know that these 3 all work different ways. any other classes of drugs you know about? NOT successors that work on same thing-please.

thanks

Read more about...
10 Replies
cajunjeff profile image
cajunjeff

Duvelisib, car nk and car t are possibilities.

in reply to cajunjeff

i had not that of duvelisib as different class than ibrutinib but i looked it up and you are correct. thanks

cajunjeff profile image
cajunjeff in reply to

You are welcome. I would add the non covalent binding btk inhibitors like GDC-0853 to the equation as well. I don’t know if technically they would be considered second generation ibrutinib drugs or not.

But as it relates to your question that seems to be exploring possible options, I think a non covalent binding btk inhibitor is very different than a btk inhibitor that binds covalently like Ibrutinib. It binds differently and might work for someone who has failed ibrutinib. I assume people who fail ibrutinib cannot expect true second generation btk inhibitors like acalabrutinib will work where ibrutinib failed, while a non covalent might work, that’s why I think of it as a different class of drugs.

Hopefully they are looking for ways to end run resistance if drugs like venetoclax and duvelisib fail too. It seems for many of us fighting Cll the game is cobbling together these drugs and hope the science of developing new drugs stays a step ahead of our Cll.

Laserjet123 profile image
Laserjet123 in reply to cajunjeff

Thanks. I suggest that you consider saying that “the drug failed the patient,” thus, not unwittingly making the person feel ashamed or somehow responsible for the drug’s failure to work with the patient. My daughter, for example, felt that she had failed when, in fact, the multiple chemos had failed her. Not what she needed after 75 weeks of chemo and three years of fighting a cancer that is very rarely cured. Thanks.

cajunjeff profile image
cajunjeff in reply to Laserjet123

First of all, I am so very sorry that your daughter had to endure such a difficult therapy for so long a time. That must have been very hard for you and her and her family and friends. Cancer is a horrible disease and everyone on here, in addition to their own cancer, probably has a person close to them fighting cancer.

I do get the distinction of saying a drug failed someone, not someone failed a drug. I will try in the future to say it’s the drug failing the person instead of the person failing the drug, even though they mean the same thing to me. I had a very difficult bout with hemolytic anemia and I failed treatments for it. It would not have helped me personally to have someone tell me the drug failed, not me, it didn’t occur to me I should be ashamed for not responding to a treatment.

I do not think most of the community on here is as sensitive to the distinction you raise. Are you a Cll patient? Just curious, with all the great info on the site it’s odd your first post would be to dig up a five month old post to suggest I was making people feel ashamed with my postings. I do try hard to give people helpful and considerate information. I do my best with the political correctness stuff, I have my own challenges with cancer and don’t parse every word I write and hope I am not offending people.

Smakwater profile image
Smakwater

Keep an eye on ibrutinib successor acalabrutinib up and coming approval for CLL and currently approved for MCL.

ncbi.nlm.nih.gov/pubmed/303...

See also - Umbralisib and Ublituximab

youtube.com/watch?v=cZR6EUV...

JM

in reply to Smakwater

i was under the impression that acalabrutinib worked the same way just had fewer side effects.

Smakwater profile image
Smakwater in reply to

You are correct. It is a second generation BTK inhibitor with a lower side affect profile, especially with regard to fib.

Smakwater profile image
Smakwater in reply to Smakwater

Afib. autocorrect is ruthless.

Hoffy profile image
Hoffy

I am on the Captivate trail with Imbruvica plus Venetoclax and it has gone very well so far.

Check out my posts,

I am 17P deleted and Unmuated,

I think Combos are the way to go!!

There is a Acalabrutinib plus V and O trial going on currently as well as others

clinicaltrials.gov/ct2/show...

Be well,

Hoffy

You may also like...

classes of drugs for cll

from each other with how they work. I used one example of each-sure many others go with them...

Cll Drugs and the Immune System

Which of the newer non-kemo drugs have the least compromising effect on our immune system. I...

Resistance-Associated Mutations in CLL Patients Treated With Novel Agents

acquired resistance mechanisms to novel agents. In 80% of patients with ibrutinib failure, acquired...

Targeted therapy drugs

people who have taken Zanubrutinib. Did you half to go through a lot of hassle getting the drug?...

Documented remission without drugs

that anyone replicate his non-drug-related treatment plan. On the other hand, I'm most intrigued,...